1. Introduction {#sec1}
===============

Recent advances in perinatal and neonatal medicine and the broader use of antenatal steroids, exogenous surfactants, sophisticated incubators and ventilator support modalities have resulted in a remarkable increase in the survival of preterm infants. Despite these advances, extremely low birth weight (ELBW) preterm infants remain at significant risk for the most frequent life-threatening complications of prematurity, such as intraventricular haemorrhage (IVH), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP) and anaemia of prematurity (AOP) [@bib1]. Preterm infants, particularly those with a birth weight less than 1500 g, are at high risk of requiring at least one, and often, multiple red blood cell (RBC) transfusions [@bib2]. The mean number of transfusions in the two largest studies ranged from 3.3 to 5.7, depending on whether restrictive or liberal transfusion guidelines were used [@bib3], [@bib4]. Nearly 50% of ELBW infants (or infants born at or before 29 weeks of gestation) receive their first transfusion during the first 2 weeks of age, and 80% receive at least one additional blood transfusion by the end of their hospitalization [@bib5].

Although RBC transfusions are a critical part of neonatal intensive care unit (NICU) stays and can be life saving for premature infants with severe anaemia or haemorrhage, they also convey risks and are costly and not easy to utilize, especially in resource-limited settings [@bib6]. Therefore, preventive strategies to start life with higher haemoglobin levels have become popular during the last few decades [@bib7]. This article reviews preventive strategies for AOP, giving particular emphasis to the enhancement of placental transfusion in the delivery room.

2. Anaemia of prematurity {#sec2}
=========================

Anaemia of prematurity is a pathological condition unlike physiologic anaemia in newborns [@bib8]. The pronounced decline in the haemoglobin (Hb) concentration that occurs in ELBW infants is usually associated with abnormal clinical signs and requires allogeneic RBC transfusions [@bib8], [@bib9]. AOP is characterized by reduced endogenous erythropoietin (EPO), reduced RBC lifespan and hypo-regenerative bone marrow [@bib7]. Non-physiologic factors related to prematurity, such as phlebotomy losses for laboratory evaluations and nosocomial infections resulting in oxidative haemolysis, also contribute to high transfusion preterm infants [@bib10].

When tissue hypoxia occurs, the transcription and expression of EPO mRNA increases, followed by an increase in erythropoiesis. Hypoxia-induced EPO expression is controlled by an enhancer element called hypoxia inducible factor-1 (HIF-1). Induction of HIF-1 binding in hypoxic cells requires RNA and protein synthesis, as well as protein phosphorylation. Sustained hypoxia is required for increasing EPO production. EPO production occurs primarily in the liver before 30 weeks of gestation (and is produced primarily in the kidney thereafter), and hypoxia is a less effective isolated stimulus for EPO production and erythropoiesis. The switch in hypoxia responsiveness and in the site of EPO production may contribute to AOP [@bib2]. Suboptimal erythropoiesis appears to be the result of the inadequate synthesis of EPO in response to hypoxia [@bib11]. EPO deficiency is greater in smaller premature infants compared to less mature infants [@bib12]. Iron, folate, vitamin B12, or vitamin E deficiencies can also contribute to inadequate erythropoiesis [@bib11].

Traditionally, AOP has been treated with frequent packed RBC transfusions [@bib13]. Among all age groups, the need for allogenic packed RBCs is common in newborns. Furthermore, preterm infants are among the most heavily transfused patient populations [@bib3], [@bib4]. The goal of packed RBC transfusions in infants with AOP is to restore or maintain oxygen delivery without increasing oxygen consumption [@bib11]. However, according to the UK Serious Hazards of Transfusion (SHOT) National Haemovigilance Scheme, an increased number of adverse events related to RBC transfusion occur in children compared to adults, more so in neonates [@bib14]. There are recognized potential adverse associations related to RBC transfusions unique to neonates. For example, associations between RBC transfusions and NEC, IVH, and chronic lung disease (CLD) as well as mortality have also been described [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22].

In recent years, most institutes have implemented more restrictive transfusion guidelines to reduce the number of transfusions and donor exposures [@bib3], [@bib4]. Two larger RCTs (the Iowa and PINT trials) have examined the transfusion criteria in the ELBW population. Both trials compared restrictive with liberal transfusion criteria for clinically relevant outcomes. Both trials developed transfusion algorithms based on the need for oxygen and the level of respiratory support in conjunction with Hb or haematocrit (Hct) levels [@bib3], [@bib4]. Both studies found that neonates in the restrictive group had fewer RBC transfusions, without an increase in mortality or morbidity. However, one critical discrepancy was present. Bell et al [@bib3] described increases in apnoea, severe IVH and periventricular leukomalacia in infants transfused with restrictive guidelines, but the trial was not designed to study these end points. Although the rates of serious outcomes were fairly high in both groups of the Kirpalani et al [@bib4] trial, they found no differences in the rates of serious outcomes between infants in the restrictive vs. liberal groups.

3. Preventive strategies for anaemia of prematurity {#sec3}
===================================================

3.1. Recombinant human EPO {#sec3.1}
--------------------------

Prevention and treatment of AOP with recombinant human EPO (r-HuEPO) has been the subject of many randomized controlled studies for over 20 years among over 3000 infants [@bib2]. Although the role of EPO in the pathophysiology of AOP is well known, neither early (2--14 days of life) nor late (2--3 weeks of life) r-HuEPO therapy, nor co-treatment with iron, vitamin B12 and folate, alters the number or volume of RBC transfusions [@bib7]. The combination of early r-HuEPO and iron does not reduce the RBC transfusion requirements in infants below 1250 g of birth weight, although the reticulocyte counts and Hct values are higher in the treatment group [@bib23]. The use of early r-HuEPO does not significantly reduce the use of one or more RBC transfusions or the number of RBC transfusions per infant compared with late r-HuEPO administration. The finding of a statistically significant increased risk of ROP (any grade) and a similar trend for ROP stage ≥3 with early EPO treatment is of great concern [@bib24]. Due to the limited benefits and the possibly increased risk of ROP, the administration of EPO is not recommended [@bib25].

The preventive strategies for AOP are summarized in [Fig. 1](#fig1){ref-type="fig"}.Figure 1Therapeutic and preventive strategies for anaemia of prematurity.

3.2. Reduction of phlebotomy losses {#sec3.2}
-----------------------------------

Iatrogenic anaemia due to the repeated removal of blood for laboratory testing is common in premature infants [@bib11]. During the first postnatal weeks, when severe neonatal cardiorespiratory illness is at its peak and frequent laboratory testing is most intense, phlebotomy loss among preterm infants is typically the most important contributor to AOP and is the reason that a transfusion is required [@bib26].

Strategies for reducing phlebotomy losses include micro-sampling, batching blood labs, cord blood sampling for immediate postnatal labs (i.e., blood type and cross-match), ordering only necessary labs, careful monitoring of phlebotomy losses, and use of blood-testing devices operated at the bedside or point of care (POC) devices [@bib27]. Madan et al [@bib28] suggested that after the use of the POC analyzer in their NICU, the number of RBC transfusions and the mean volume of RBC transfusions decreased by 43% and 46%, respectively, in infants with birth weights less than 1 kg. Widness et al [@bib29] found that infants who were examined with an in-line umbilical artery catheter analyser received a significantly lower amount of RBCs than infants who were examined according to regular laboratory use during the first week of life. However, these strategies, which are dependent on a sophisticated device, are limited by economic conditions, especially in developing countries.

3.3. Enhancing placental transfusion {#sec3.3}
------------------------------------

In animal studies, it was found that immediate cord clamping after birth results in the accumulation of approximately 30%--50% of the feto-placental blood volume in the placental unit and leaves the newborn with the same amount of reduced blood volume [@bib30], [@bib31]. Approximately one-half of the feto-placental blood volume (nearly 110 ml/kg) remains outside the newborn infant\'s circulation at 30 weeks of gestation if the umbilical cord is clamped immediately [@bib31], [@bib32]. Aladangady et al [@bib31] were the first group that demonstrated that the blood volume of ELBW preterm newborns could be increased by delayed cord clamping (DCC) for 30--90 s in both vaginal and CS deliveries. The placental transfusion via DCC was more marked after vaginal deliveries and seemed to be more apparent for preterm infants with lower gestational ages [@bib31].

Delayed cord clamping and umbilical cord milking (UCM) are the main methods for enhancing placental transfusion. The key difference between DCC and UCM is the mechanism of cord blood transfer to the infant. In DCC, a passive transfer of additional blood volume occurs at a slow rate, mostly by uterine contractions, whereas in UCM, an active transfer of additional blood volume occurs at a rapid rate and within a short time [@bib33].

3.4. Delayed cord clamping {#sec3.4}
--------------------------

A recent Cochrane meta-analysis of data from 15 randomized trials with a total of 738 infants who were born between 24 and 36 weeks\' gestation found that DCC for 30--120 s, rather than immediate clamping, seems to be associated with less need for transfusion, better circulatory stability, less IVH and a lower risk for NEC [@bib34]. Concerns about polycythaemia and hyperbilirubinemia as well as delays in transition were not included in the review due to the heterogeneity of the trials [@bib34]. In December 2012, the American College of Obstetricians and Gynecologists (ACOG) recommended a 30--60 s delay in umbilical cord clamping for all preterm deliveries because of the associated neonatal benefits, including increased blood volume, reduced need for RBC transfusion, and decreased incidence of IVH in preterm infants [@bib35]. The "European Consensus Guidelines on Resuscitation of the Preterm Infant" also recommended a delay of 30--60 s before clamping the umbilical cord [@bib36]. In a clinical trial on neurodevelopmental outcomes in preterm infants by Mercer et al [@bib37], 58 infants who were randomized to DCC (30--45 s) had similar Bayley II scores with the control group of infants at seven months of age. A regression model of the effects of DCC on motor scores controlling for gestational age, IVH, bronchopulmonary dysplasia, sepsis, and male gender suggested higher motor scores in male infants with DCC [@bib38]. More recently, Andersson et al [@bib38] found that DCC compared with immediate cord clamping improved scores in the fine-motor and social domains at 4 years of age, especially in boys who were born at term gestation.

Although DCC has been adopted by many centers in Canada and Europe, especially in preterm populations, it has not gained wide acceptance in the United States [@bib39]. Some researchers have noted that DCC may lead to delayed resuscitation and heat loss in infants who have a lower birth weight or a shorter gestational age [@bib34], [@bib40]. However, it is already known that neonates who require resuscitation also need a placental transfusion as much or more so than do healthy newborns [@bib41]. More recently, Mercer and Erickson-Owens [@bib41] suggested that an intrapartum care provider can achieve a placental transfusion for a distressed neonate by UCM several times or can resuscitate the neonate at the perineum with an intact cord. Bringing the resuscitation to the mother\'s bedside is a novel concept and supports an intact cord. Adopting resuscitation with an intact umbilical cord in a hospital setting will take concentrated effort and teamwork by midwifery, obstetric, pediatric, and nursing staff [@bib41]. They also suggested that UCM can be performed quickly by any intrapartum care provider within the current Neonatal Resuscitation Program guidelines [@bib41]. Furthermore, a recent Cochrane review concluded that larger multi-center studies are essential and demand international collaboration to provide a scientific rationale for improving the delivery and resuscitation of the preterm infant [@bib34]. However, more recently, the 2015 ILCOR systematic review for the neonatal resuscitation program suggested that DCC after 30 s is reasonable for both term and preterm infants who do not require resuscitation at birth. They did not recommend the routine use of UCM for ELBW infants due to concerns regarding the safety of rapid changes in blood volume by UCM for extremely preterm infants [@bib42].

3.5. Umbilical cord milking {#sec3.5}
---------------------------

An alternative to DCC is UCM, in which the unclamped umbilical cord is grasped and blood is pushed toward the infant several times before it is clamped to auto-infuse blood into a preterm neonate [@bib43]. Although Beck [@bib44] proposed this procedure for premature babies in 1941, the first randomized controlled trial on UCM in premature babies was published by Hosono et al [@bib40] in 2008. Hosono et al [@bib40] were able to demonstrate reductions in both the need for RBC transfusion during the first 3 weeks of life and the total length of NICU hospitalization with UCM. They reported that the percentage of infants who had no RBC transfusions was significantly higher in the UCM group (65% vs. 30%) [@bib40]. This study showed that UCM is a simple and cost free method that can reduce the number of RBC transfusions in preterm infants born at less than 29 weeks\' gestation [@bib40].

A second randomized controlled trial to compare UCM with ICC was published by March et al [@bib45] in 2013. They showed that preterm infants whose cords were milked had higher Hb levels at birth and had significantly fewer transfusions in the first 14 days of life. Although the difference in the incidence of the neonatal transfusions did not reach statistical significance in their study, a 14.1% decrease was observed in the UCM group during the first 28 days of life [@bib45]. Katheria et al [@bib46] designed a randomized controlled trial including 60 preterm infants to investigate the effect of UCM on systemic blood flow. They found that preterm infants randomized to UCM had greater measures of superior vena cava flow and right ventricular output in the first 6 and 30 h of life. In addition, neonates receiving UCM also had greater serum Hb levels, received fewer blood transfusions, had fewer days on oxygen therapy, and had less frequent use of oxygen at 36 weeks\' corrected postmenstrual age [@bib46]. Our study group [@bib47] previously demonstrated that UCM resulted in higher Hb levels in very low birth-weight preterm infants within the first day of life. However, the number and volume of RBC transfusions was nearly equal between the UCM and ICC groups by the end of 14 and 35 days of life and during the total length of NICU stay in our study, probably due to excessive phlebotomy losses.

More recently, Kilicdag et al [@bib48] found that the absolute neutrophil counts (ANCs) were lower and the frequency of neutropenia was higher in the UCM group in their RCT. In contrast to former RCTs, they did not find any difference between the UCM and ICC groups in terms of the Hb and Hct levels [@bib48].

In addition to the trials that compared UCM with ICC, there are two RCTs that aim to compare UCM with DCC [@bib43], [@bib49]. Rabe et al [@bib49] designed a RCT including 58 preterm infants who were randomized either to UCM or DCC for 30 s and found that the number of infants who did not need a RBC transfusion was not significantly different between the 2 intervention groups (52% for DCC and 37% for UCM). Katheria et al [@bib43] found that UCM provides higher initial Hb levels, higher blood pressure, and improved systemic blood flow and urine output in preterm infants delivered by caesarean delivery. However, they did not find any difference in these parameters in infants delivered by vaginal delivery and speculated that more blood remained in the placenta when a neonate was delivered by caesarean section because the anaesthetic and surgical interventions interfered with the active contraction of the uterine muscles to expel the placenta [@bib43]. Katheria et al [@bib43] also suggested that UCM might be preferable in preterm infants delivered by caesarean delivery, particularly in newborns when immediate resuscitation is needed.

In total, umbilical cord milking has been studied in 8 RCTs and 4 controlled trials over the past two decades in preterm infants (n = 968) [@bib39], [@bib40], [@bib43], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53]. These trials are summarized in [Table 1](#tbl1){ref-type="table"}. The heterogeneity of the methodologies, primary outcomes and UCM techniques of these trials is remarkable. Furthermore, the local guidelines for RBC transfusions were not specified in most of these trials, except for the studies by Hosono et al [@bib40], Rabe et al [@bib49] and Alan et al [@bib47]. Hosono et al [@bib40] and Rabe et al [@bib49] used more restrictive guidelines for RBC transfusion than the guideline Alan et al [@bib47] utilized. In addition, phlebotomy losses were also not specified in most of these trials, except the trials performed by Hosono et al [@bib40], Rabe et al [@bib49] and Alan et al [@bib47] ([Table 1](#tbl1){ref-type="table"}).Table 1A summary of the studies on the effect of umbilical cord milking in preterm infants.PopulationRandomizationBlindnessUCM techniqueMode of deliveryControl conditionPhlebotomyGuidelines for RBC transfusionPrimary outcomes1Katheria et al [@bib39], 2015154 infants, 23--32 wkYesYes20 cm in 2 s, 4 timesCDDCC with 45 sNot reportedNot reportedSuperior vena cava flow and right ventricular output2Hosono et al [@bib48], 201540 infants, \<29 wkNoNo20 cm within 2 s, 1 timeCD, NSVDUCM with 20 cm within 2 s, 2--3 timesThe number of RBC transfusions and the probability of not needing a RBC transfusion3Kilicdag et al [@bib46], 201554 infants, ≤32 wkYesNo20 cm in 2 s, 4 timesCDICCNot reportedNot reportedImpact of UCM on Absolute neutrophil counts4Patel et al [@bib33], 2014318 infants, \<30 wkNoNo20 cm within 2 s, 2--3 timesCD, NSVDICCNot reportedNot reportedSevere IVH, NEC, death before discharge5Katheria et al [@bib40], 201460 infants, 23 wk--31 wk 6 dYesYes20 cm in 2 s, 3 timesCD, NSVDICCNot reportedNot reportedSystemic blood flow (superior vena cava flow)6Alan et al [@bib43], 201444 infants, ≤32 wkYesNo25--30 cm, 5 cm in 1 s, 3 timesCD, NSVDICCThe median of 38 ml/kg in UCM and 38 ml/kg in ICC groups during the first 35 days of lifeYesthe number and volume of RBC transfusions7Katheria et al [@bib49], 201441 infants, 23 wk--31 wk 6 dYesYes (Partial)20 cm in 2 s, 3 timesCD, NSVDICCNot reportedNot reportedHR, SpO2, MAP, and FiO2 in the delivery room8Christensen et al [@bib50], 2014First: 32 infants, 23--40 wk. Second: 20 infants, \<32 wkNoNoIn 10--15 s, 2--4 timesCD, NSVDICCNot reportedNot reportedHyperviscosity in preterm infants9March et al [@bib42], 201375 infants, 24--28 completed wksYesNo20 cm, 3 timesCD, NSVDICCNot reportedNot reportedThe need for RBC transfusion10Takami et al [@bib51], 201250 infants, \<29 wkNoNo20 cm in a s, 2--3 timesCD, NSVDICCNot reportedNot reportedCerebral and systemic perfusion11Rabe et al [@bib41], 201158 infants, 24 wk--32 wk 6 dYesNo20 cm in 2 s, 4 timesCD, NSVDDCC with 30 sThe median of 19 ml in UCM group 23 ml in DCC group during the first 42 d of lifeYesTo compare two strategies for enhancing placental transfusion12Hosono et al [@bib38], 200840 infants, 24-28 wkYesNo20 cm in 2 s, 2--3 timesCD, NSVDICC16 ± 3 ml/kg in the UCM group and 16.7 ± 4.8 ml/kg in the control group during first 4 wk of lifeYesThe need for RBC transfusion and morbidities[^1]

To our knowledge, there are three meta-analyses concerning UCM in preterm infants. A meta-analysis by Al-Wassia and Shah [@bib33] evaluating the safety and efficacy of UCM at birth concluded that there was a lower risk for an oxygen requirement at 36 weeks and IVH of all grades, but no difference in the risk of mortality. A recent meta-analysis by Dang et al [@bib54] found that UCM at preterm birth was comparatively safe and associated with a lower RBC exposure and lower incidence of IVH, NEC and death. An additional meta-analysis by Backes et al [@bib55] concluded that enhanced placental transfusion (DCC or UCM) at birth provided better neonatal outcomes (reductions in overall mortality, lower risk of IVH, and decreased RBC transfusion incidence) in very preterm neonates.

Although the data on neurodevelopmental outcomes in premature infants are limited, some authors strongly suggest that UCM should no longer be considered experimental; rather, it is a proven intervention that ensures that premature newborns receive an adequate placental transfusion at birth [@bib44].

4. Conclusion {#sec4}
=============

Due to the increased survival of ELBW infants, AOP has become a common and serious problem for all NICUs. RBC transfusion is the only proven treatment strategy for AOP. However, there are no physiological or laboratory markers for accurate indicators of requiring RBC transfusion other than Hb values. Placental/umbilical cord blood was an untapped resource for premature infants until the last few decades. After the results and recommendations of the trials and meta-analyses failed to demonstrate that neither prevention nor treatment of AOP with r-HuEPO was effective and safe, the issue of enhanced placental transfusion has been raised. The methods for enhancing placental transfusion have many proven beneficial effects in preterm infants. This strategy clearly results in higher Hb levels at birth and a reduced need for RBC transfusions, as well as creating a better haemodynamic status during the initial hours of life. To date, the enhancement of placental transfusion in the delivery room either by DCC or UCM seems to be the best preventive measure for AOP. The effects of placental transfusion probably vary in vaginal deliveries and caesarean sections. Although the safety of rapid changes in blood volume via UCM for preterm infants remains a concern, there are no data for haemodynamic adverse effects up to now. Furthermore, studies assessing neurodevelopmental outcomes are insufficient. However, resuscitation events are not reported consistently, precluding the determination of the optimal cord clamping practice among neonates born severely depressed or requiring immediate resuscitation. Large-scale, randomized clinical trials of enhanced placental transfusion strategies to assess long-term neurodevelopmental and neurologic sequelae are needed.

One should also keep in mind that blood elements other than red blood cells are transfused via DCC or UCM and that the clinical results of the transfusion of these blood elements have not been evaluated.

5. Recommendations {#sec5}
==================

•Enhancing placental transfusion by DCC (at least for 30 s) or UCM (2--4 times) during delivery seems to be the best approach for preterm infants who do not require resuscitation. Sufficient data for performing resuscitation with intact cords are still lacking.•Cord blood should be used for initial laboratory tests.•Phlebotomy losses should be reduced.•Nutrition support with vitamins (folate, B12 and vitamin E) and iron should be optimized.•Individual transfusion guidelines should be established and utilized.
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[^1]: Abbreviations: CD: Caesarean delivery, HR: Heart rate, ICC: Immediate cord clamping, NSVD: Normal spontaneous vaginal delivery, RBC: Red blood cell, IVH: Intraventricular haemorrhage, MAP: Mean arterial pressure, UCM: Umbilical cord milking, wk: week.
